Study Summary
This is a phase II clinical study to evaluate the safety and efficacy of pCAR-19 B cell autologous infusion preparation in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.
Want to learn more about this trial?
Request More InfoInterventions
pCAR-19B cellsBIOLOGICAL
Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Beijing Children's Hospital.Capital Medical University | Beijing | Beijing Municipality | China |
| Beijing GoBroad Boren Hospital | Beijing | Beijing Municipality | China |
| Pediatric Hematology department of Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology | Wuhan | Hubei | China |
| Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology | Wuhan | Hubei | China |
| Xiehe Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology | Wuhan | Hubei | China |
| The Second Xiangya Hospital, Central South University | Changsha | Hunan | China |
| Children's Hospital Of Soochow University | Suzhou | Jiangsu | China |
| The First Affiliated Hospital Of Nanchang University | Nanchang | Jiangxi | China |
| West China Second University Hospital,Sichuan University | Chengdu | Sichuan | China |
| Institute Of Hematology&Blood Diseases Hospital,Chinese Academy Of Medicai Sciences | Tianjin | Tianjin Municipality | China |